Pediatric vaccines are given to a children in its age from 0 – 18 years of age. Congenital Zika is one of the latest pediatric vaccine which found relation in davsstating defects in infants and Zika virus. This leads to contribute in the growth of the pediatric vaccine market with a CAGR of approx 15.65% during forecast period 2016-2023.The global pediatric vaccine market is driven by increasing government focus on immunization programs , Increase in the number of disease among children such as TB, Hepatitis etc. and government funding for the vaccine development. High growth of healthcare sector globally and increase in the expenditure in health industry are the opportunity for the players involved in the pediatricpaedaitic vaccine market to grow. However, huge capital investment and stringent government regulation for the development of new vaccines and standrads to be followed by governmnrt regarding pediatric vaccine is hampering the demand of the pediatric vaccine market. The major challenge faced by pediatric vaccine market are vaccine cost and inadequate access to vaccine.
Geographically the pediatric vaccine market is bifurcated into North America, Europe, Asia Pacific and RoW. North America gained highest revenue share and is dominating region in pediatric vaccine market. Introduction of new vaccines for all type of diseases and rise in the frequency of occurrence of infectious diseases such as diphtheria, tuberculosis, hepatitis, and pneumococcal disease is aiding the growth of pediatric vaccine market in North America. Moreover, Asia Pacific is the fastest growing region in global pediatric vaccine market due to high annual birth rate which increase the pediatric population in Asian countries such as India, China etc.
Global pediatric vaccine market is segmented on the basis of technology, type, disease indication and end-user. On the basis of disease indication, the pediatric vaccine market is classified as MMR, DTP, influenza, hepatitis, meningococcal disease, pneumococcal disease, human papilloma virus, polio, rotavirus, varicella and others. The technology used in the pediatric market includes conjugate vaccines, inactivate & subunit vaccines live attenuated vaccines, toxoid vaccines and recombinant vaccines. Type is segmented into monovalent vaccines and multivalent vaccines. Monovalent vaccine segment held maximum market share in term of revenue and expected to continue to grow throughout the forecast period 2016-2023. Pneumococcal disease is the growing segment due to increase in the number of patients of pneumococcal infection. The end-user of pediatric vaccine market includes pediatric and adults.
Some of the major players in the pediatric vaccine market are Pfizer, Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi Pasteur (France), Merck & Co., Inc. (U.S.), Medimmune, LLC (U.S.), Astellas Pharma Inc. (JAPAN) and Others. These companies using various strategies such as merger & acquisition, collaboration, partnership and product launch.